1. Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Patient Case Work-Up

6. Guidelines for Molecular Testing

7. Considerations for Molecular Testing

8. Patient Case Test Results

9. Importance of Waiting for Molecular Test Results

10. PD-L1 Treatment vs Targeted Therapy

11. First-Line Treatment Selection

12. CNS Penetration

13. Considerations for Sequencing Osimertinib

14. Improving Outcomes With First- and Second-Generation EGFR TKIs

15. Patient Case Hypotheticals

16. Patient Case Disease Progression

17. Mechanisms of Resistance to Osimertinib Data From Second-Line Treatment

18. Mechanisms of Resistance to Osimertinib Preliminary Data From First-Line Treatment

19. Liquid vs Tissue Biopsy

20. Patient Case Disease Progression

21. Chemoimmunotherapy

22. Concluding Remarks

23. Abbreviations